The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

Defects in apoptosis can promote tumorigenesis and impair responses of malignant B cells
to chemotherapeutics. Members of the B-cell leukemia/lymphoma-2 (BCL-2) family of …

Background The combination of ibrutinib and venetoclax has been shown to improve
outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with …

Background GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-
venetoclax in older patients and/or those with comorbidities with previously untreated …

PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal
residual disease (MRD)-guided treatment discontinuation following completion of first-line …

CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged≤ 70 years
with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort …

Background Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of
B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

Intrinsic apoptosis is controlled by the BCL-2 family of proteins but the complexity of intra-
family interactions makes it challenging to predict cell fate via standard molecular biology …

Background Both continuous therapy with acalabrutinib and fixed-duration therapy with
venetoclax–obinutuzumab are effective for previously untreated chronic lymphocytic …